Literature DB >> 12052634

AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.

R N Jones1, T R Anderegg, L M Deshpande.   

Abstract

AZD2563, a novel oxazolidinone, was tested against 10 well characterized multiple-resistant strains of staphylococci and viridans group or beta-hemolytic streptococci using kill curve kinetic methods. Generally, AZD2563 demonstrated bacteriostatic action and modest concentration-dependent cidal activity against a minority of strains of both genera. When combined with gentamicin (MIC/4 concentration), rapid bactericidal action was observed against all streptococci tested, but not against the staphylococci. No enhanced activity was noted when AZD2563 was added to subinhibitory concentrations of vancomycin. Linezolid used as a control, showed the same characteristics, confirming that AZD2563 possesses activity comparable to other agents in the oxazolidinone class. AZD2563 remained active (MIC, < or = 1 microg/ml) against all 10 strains tested.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052634     DOI: 10.1016/s0732-8893(02)00360-7

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  In Vitro and In Vivo Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis.

Authors:  Shaochen Guo; Bin Wang; Lei Fu; Xi Chen; Weiyan Zhang; Haihong Huang; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

2.  In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus.

Authors:  Shveta Rani Singh; Alfred E Bacon; David C Young; Kimberly A Couch
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

3.  Zerumbone from Zingiber zerumbet (L.) smith: a potential prophylactic and therapeutic agent against the cariogenic bacterium Streptococcus mutans.

Authors:  Thiago Moreira da Silva; Carlos Danniel Pinheiro; Patricia Puccinelli Orlandi; Carlos Cleomir Pinheiro; Gemilson Soares Pontes
Journal:  BMC Complement Altern Med       Date:  2018-11-13       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.